Pfizer Inc. (PFE) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 29, 2026. Pfizer operates through two segments: Biopharma (the only reportable segment) and Pfizer CentreOne (PC1). The company manages its commercial operations through a global structure effective Q1 2026, which includes a new Global Hospital and Biosimilars Division. The company is a large accelerated filer.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Total Revenues | $14.45 billion | $13.72 billion | +5.4% |
| Net Income (Attributable to Pfizer) | $2.69 billion | $2.97 billion | -9.4% |
| Diluted EPS | $0.47 | $0.52 | -9.6% |
| Operating Cash Flow | $2.62 billion | $2.34 billion | +12.0% |
| Cost of Sales Margin | 24.6% | 20.7% | -3.9 pts |
| Effective Tax Rate | 14.6% | (6.8)% | N/A |
| Total Debt (Short + Long Term) | $64.46 billion | $64.79 billion | -0.5% |
| Cash & Short-term Investments | $13.08 billion | $13.60 billion | -3.8% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 5% year-over-year, driven by a 2% operational increase and a 3% favorable foreign exchange impact. Excluding Comirnaty and Paxlovid, operational revenue grew 7%.
- Profitability Decline: Net income decreased primarily due to higher Cost of Sales (up 25%) and increased R&D expenses (up 13%), partially offset by a significant reduction in restructuring charges (down 85%).
- Product Performance:
- Declines: Comirnaty (-59%) and Paxlovid (-63%) revenues dropped significantly due to lower demand and government purchases. Prevnar family (-1%) and Ibrance (-1%) saw slight operational declines.
- Growth: Padcev (+39%), Nurtec ODT/Vydura (+41%), Lorbrena (+32%), and Abrysvo (+31%) drove operational growth. Eliquis grew 8% operationally.
- Acquisitions & Investments: Pfizer completed the acquisition of Metsera (Nov 2025) for $8.0 billion. In Q1 2026, the company recorded $137 million in acquired in-process R&D expenses. The company also exited its 11.7% investment in ViiV in Q2 2026 (March 31), receiving $1.875 billion in proceeds.
- Restructuring: Restructuring charges dropped to $100 million from $678 million in the prior year, reflecting the winding down of major cost-reduction initiatives.
Guidance, Outlook, and Risks
- Patent Expiries: Management expects an unfavorable revenue impact of approximately $1.5 billion in 2026 due to patent-based or regulatory exclusivity expiries, with the rate of reduction expected to accelerate in subsequent years.
- Regulatory & Pricing: The Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program (MDPNP) became effective for Eliquis on January 1, 2026. Negotiated prices for Ibrance and Xtandi are expected in 2027.
- Tariffs: On April 2, 2026, the U.S. Government announced Section 232 tariffs on imported patented pharmaceuticals (up to 100% duty), set to phase in on July 31, 2026. Pfizer is negotiating a tariff agreement with exemptions for onshore investment commitments.
- Cost Synergies: The company expects to generate approximately $600 million in annual cost synergies from the Metsera acquisition by the end of 2026.
- Legal Proceedings: Significant ongoing litigation includes patent disputes regarding Comirnaty (Moderna, GSK, Arbutus), Paxlovid (Enanta), and product liability suits related to Zantac and Depo-Provera. Pfizer settled certain Zantac state actions in April 2026 on terms not material to the company.
Investor Verification Checklist
- COVID-19 Revenue Trajectory: Verify the sustainability of the steep decline in Comirnaty and Paxlovid revenues and the impact on future inventory levels.
- Tariff Negotiation Status: Confirm the outcome of Pfizer's negotiations with the U.S. Government regarding Section 232 tariffs and the potential financial impact if an agreement is not reached by July 2026.
- Metsera Integration: Monitor the progress of the Metsera integration and the realization of the projected $600 million in annual cost synergies.
- Patent Cliff Management: Assess the company's ability to offset the projected $1.5 billion revenue loss from patent expiries in 2026 with new product launches (e.g., Veppanu, Padcev expansions).
- Legal Reserves: Review the adequacy of reserves for ongoing product liability litigation (Zantac, Depo-Provera) and patent infringement suits (Comirnaty).